Tumour‐induced alterations in single‐nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism

Tumour-induced skeletal muscle wasting in the context of cancer cachexia is a condition with profound implications for patient survival. The loss of muscle mass is a significant clinical obstacle and is linked to reduced tolerance to chemotherapy and increased frailty. Understanding the molecular mechanisms driving muscle atrophy is crucial for the design of new therapeutics.